公开(公告)号：US20120142769A1

公开(公告)日：2012-06-07

申请号：US13379793

申请日：2010-06-21

Applicant: Moise A. Khayrallah ,  Gary Bream ,  Stephen E. Butts ,  Susan Marie Melnick ,  Duncan Taylor

Inventor： Moise A. Khayrallah ,  Gary Bream ,  Stephen E. Butts ,  Susan Marie Melnick ,  Duncan Taylor

IPC: A61K31/27 ,  A61P43/00

CPC classification number: A61K31/27 ,  A61K31/137 ,  A61K31/175 ,  A61K45/06 ,  C07C271/20 ,  A61K2300/00

Abstract: The present invention relates to the use of compounds of the invention for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments.

Abstract translation: 本发明涉及本发明化合物用于治疗和/或预防疲劳的用途，包括与疾病或治疗有关的疲劳。

公开(公告)号：US20080103147A1

公开(公告)日：2008-05-01

申请号：US11928980

申请日：2007-10-30

Applicant: Erik Wong ,  Saeeduddin Ahmed ,  Robert Marshall ,  Robert McArthur ,  Duncan Taylor ,  Lars Birgerson ,  Pasquale Cetera

Inventor： Erik Wong ,  Saeeduddin Ahmed ,  Robert Marshall ,  Robert McArthur ,  Duncan Taylor ,  Lars Birgerson ,  Pasquale Cetera

IPC: A61K31/5375 ,  A61P25/00 ,  A61P25/18 ,  A61P3/04

CPC classification number: A61K31/5375 ,  A61K31/00 ,  A61K31/537

Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. Examples of such compounds include reboxetine, and more particularly racemic reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

Abstract translation: 公开了用于治疗患有或预防人遭受生理或精神疾病，病症或抑制去甲肾上腺素再摄取的病症的人的方法和组合物。 这些化合物的实例包括瑞波西汀，更特别是外消旋的瑞波西汀。 方法通常包括施用治疗量的这种组合物。 还公开了来自组合物的药物的制剂，以及该组合物在制备药物中治疗患有或预防人类遭受生理或精神疾病，病症或病症的人的用途。

公开(公告)号：US20060264436A1

公开(公告)日：2006-11-23

申请号：US11460775

申请日：2006-07-28

Applicant: Erik Wong ,  Saeeduddin Ahmed ,  Robert Marshall ,  Robert McArthur ,  Duncan Taylor

Inventor： Erik Wong ,  Saeeduddin Ahmed ,  Robert Marshall ,  Robert McArthur ,  Duncan Taylor

IPC: A61K31/537

CPC classification number: A61K31/5375 ,  A61K31/00 ,  A61K31/537

Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

Abstract translation: 公开了用于治疗患有或预防人遭受生理或精神疾病，病症或抑制去甲肾上腺素再摄取的病症的人的方法和组合物。 组合物包含具有至少约5000的5-羟色胺（N 1 O）/去甲肾上腺素（KI）的药理学选择性的化合物。这些化合物的实例包括瑞波西汀等 优选光学纯的（S，S）对映异构体。 方法通常包括施用治疗量的这种组合物。 还公开了来自组合物的药物的制剂，以及该组合物在制备药物中治疗患有或预防人类遭受生理或精神疾病，病症或病症的人的用途。

公开(公告)号：US20060160776A1

公开(公告)日：2006-07-20

申请号：US10854586

申请日：2004-05-26

Applicant: Diane Stephenson ,  Duncan Taylor

Inventor： Diane Stephenson ,  Duncan Taylor

IPC: A61K31/663 ,  A61K31/5377 ,  A61K31/415 ,  A61K31/50 ,  A61K31/365 ,  A61K31/353 ,  A61K31/655

CPC classification number: A61K31/33

Abstract: The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a cannabinoid agent in combination with a cyclooxygenase-2 selective inhibitor.

Abstract translation: 本发明提供了用于治疗受试者的中枢神经系统损伤的组合物和方法。 更具体地，本发明提供了用于治疗中枢神经系统缺血状况或中枢神经系统创伤性损伤的组合疗法，其包括与环加氧酶-2选择性抑制剂组合施用大麻素药物的受试者。

公开(公告)号：US20060135521A1

公开(公告)日：2006-06-22

申请号：US11349331

申请日：2006-02-07

Applicant: Erik Wong ,  Saeeduddin Ahmed ,  Robert Marshall ,  Robert McArthur ,  Duncan Taylor

Inventor： Erik Wong ,  Saeeduddin Ahmed ,  Robert Marshall ,  Robert McArthur ,  Duncan Taylor

IPC: A61K31/537

CPC classification number: A61K31/5375 ,  A61K31/00 ,  A61K31/537

Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

Abstract translation: 公开了用于治疗患有或预防人遭受生理或精神疾病，病症或抑制去甲肾上腺素再摄取的病症的人的方法和组合物。 组合物包含具有至少约5000的5-羟色胺（N 1 O）/去甲肾上腺素（KI）的药理学选择性的化合物。这些化合物的实例包括瑞波西汀等 优选光学纯的（S，S）对映异构体。 方法通常包括施用治疗量的这种组合物。 还公开了来自组合物的药物的制剂，以及该组合物在制备药物中治疗患有或预防人类遭受生理或精神疾病，病症或病症的人的用途。

公开(公告)号：US20060128705A1

公开(公告)日：2006-06-15

申请号：US11349373

申请日：2006-02-07

Applicant: Erik Wong ,  Saeeduddin Ahmed ,  Robert Marshall ,  Robert McArthur ,  Duncan Taylor

Inventor： Erik Wong ,  Saeeduddin Ahmed ,  Robert Marshall ,  Robert McArthur ,  Duncan Taylor

IPC: A61K31/537

CPC classification number: A61K31/5375 ,  A61K31/00 ,  A61K31/537

Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

Abstract translation: 公开了用于治疗患有或预防人遭受生理或精神疾病，病症或抑制去甲肾上腺素再摄取的病症的人的方法和组合物。 组合物包含具有至少约5000的5-羟色胺（N 1 O）/去甲肾上腺素（KI）的药理学选择性的化合物。这些化合物的实例包括瑞波西汀等 优选光学纯的（S，S）对映异构体。 方法通常包括施用治疗量的这种组合物。 还公开了来自组合物的药物的制剂，以及该组合物在制备药物中治疗患有或预防人类遭受生理或精神疾病，病症或病症的人的用途。

公开(公告)号：US20050113433A1

公开(公告)日：2005-05-26

申请号：US10845009

申请日：2004-05-13

Applicant: Diane Stephenson ,  Duncan Taylor ,  Stephen Arneric

Inventor： Diane Stephenson ,  Duncan Taylor ,  Stephen Arneric

IPC: A61K31/14 ,  A61K45/06 ,  A61K31/415 ,  A61K31/195

CPC classification number: A61K45/06 ,  A61K31/14 ,  A61K2300/00

Abstract: The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a cholinergic agent in combination with a phenyl acetic acid cyclooxygenase-2 selective inhibitor.

Abstract translation: 本发明提供了用于治疗受试者的中枢神经系统损伤的组合物和方法。 更具体地，本发明提供了用于治疗中枢神经系统缺血状况或中枢神经系统创伤性损伤的组合疗法，其包括向苯乙酸环氧合酶-2选择性抑制剂组合施用胆碱能药物的对象。

公开(公告)号：US20050026919A1

公开(公告)日：2005-02-03

申请号：US10844921

申请日：2004-05-13

Applicant: Diane Stephenson ,  Duncan Taylor ,  Stephen Arneric

Inventor： Diane Stephenson ,  Duncan Taylor ,  Stephen Arneric

IPC: A61K20060101 ,  A61K31/365 ,  A61K31/415 ,  A61K31/50 ,  A61P9/10

CPC classification number: A61K45/06

Abstract: The present invention provides compositions and methods for the treatment of reduced blood flow to the central nervous system or traumatic injury to the central nervous system in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or traumatic injury comprising the administration to a subject of a cholinergic agent in combination with a cyclooxygenase-2 selective inhibitor.

Abstract translation: 本发明提供了用于治疗对中枢神经系统的血液流量减少或受试者中枢神经系统的创伤性损伤的组合物和方法。 更具体地，本发明提供了用于治疗中枢神经系统缺血状况或创伤性损伤的组合疗法，其包括与环氧合酶-2选择性抑制剂组合施用胆碱能药物的受试者。

公开(公告)号：USD684787S1

公开(公告)日：2013-06-25

申请号：US29435488

申请日：2012-10-24

Applicant: Duncan Taylor Scotch Whisky Limited

Designer： Euan Coutts Shand

公开(公告)号：US07370655B2

公开(公告)日：2008-05-13

申请号：US10346604

申请日：2003-01-17

Applicant: Duncan Taylor

Inventor： Duncan Taylor

IPC: A61F11/00

CPC classification number: A61F11/08 ,  B23K26/389 ,  B23K2103/42 ,  B23K2103/50 ,  B29C66/126 ,  B29C66/5344 ,  B29C66/612 ,  B29C66/727 ,  B29L2031/737 ,  B29L2031/753 ,  Y10T29/49995

Abstract: A method of forming an earplug is provided including removing a material of the earplug by laser ablation. An earplug is positioned proximate a laser, a portion of the earplug to be ablated is identified, the laser is activated so as to direct an emitted laser light toward the portion to be ablated, and the portion to be ablated is removed by laser ablation. The invention is also directed to an earplug including a feature formed by laser ablation.

Abstract translation: 提供了一种形成耳塞的方法，包括通过激光烧蚀去除耳塞的材料。 耳塞靠近激光器定位，识别要消除的耳塞的一部分，激光被激活，以将发射的激光导向待烧蚀的部分，并且通过激光烧蚀去除要消融的部分。 本发明还涉及包括通过激光烧蚀形成的特征的耳塞。